37 Supported by research
Younger people with severe COVID-19 complications have a high frequency of obesity, and elevated uric acid may play a role in their increased risk.
"younger people, especially the younger people who have serious COVID-related complications, there's a high frequency of obesity in that group. And we think that one of the thoughts is that the uric acid may be playing a role in why they're at increased risk." (said at 0:00:00)
The speaker accurately states two related observations: obesity is a prominent risk factor for severe COVID-19 outcomes in younger demographics, and researchers have hypothesized that elevated uric acid (hyperuricemia)—which is strongly linked to obesity and metabolic syndrome—may contribute to the increased risk of severe COVID-19 complications and organ damage. Observational cohort data in hospitalized COVID-19 patients show that higher serum uric acid levels are independently associated with acute kidney injury, major adverse kidney events, and in-hospital mortality in a dose-dependent manner. Because the available evidence is observational and the causal role of uric acid remains hypothetical, the overall certainty of evidence is low.
The human body manufactures fructose via the polyol pathway, which is activated by hypoxia, elevated sodium, dehydration, and high glucose.
"We actually make fructose in the body through activation of what is called the polyol pathway that can be activated by hypoxia, by elevated sodium, by being dehydrated, by having high glucose." (said at 0:00:34)
The speaker's statement is accurate. Endogenous fructose is produced through the polyol pathway (in which aldose reductase converts glucose to sorbitol, and sorbitol dehydrogenase converts sorbitol to fructose). Aldose reductase is activated under conditions of high glucose, osmotic stress (such as high sodium or dehydration), and tissue hypoxia/ischemia as a conserved metabolic and osmoregulatory response.
A study showed a 70-fold increase in mitochondria in white blood cells in people placed on a low-sodium, low-fructose diet.
"the study I pulled last night about how you demonstrated in white blood cells an incredible 70-fold increase in mitochondria in people going on a low-sodium, low-fructose diet." (said at 0:02:08)
A 2013 randomized trial led by Richard J. Johnson evaluated the effect of dietary fructose and sodium restriction over 8 weeks in 36 overweight and prehypertensive subjects. In the group placed on the low-sodium, low-fructose diet, leukocyte mitochondrial DNA (mtDNA) relative copy number increased from 1.9 at baseline to 147.2 at week 8, representing an approximate 77-fold increase.
Only a small amount of dietary fructose enters the brain, but consumption of sugar, salt, and high-glycemic carbohydrates stimulates endogenous fructose production in the brain.
"when you eat fructose, only a small amount of fructose gets to the brain. So you would think that the brain would be safe from the effects of fructose to some extent. But what happens is the brain can actually make fructose. And when you eat sugar, we don't totally know the mechanism, but it seems that that stimulates fructose production in the brain. So sugar and salt and high-glycemic carbs all seem to drive fructose production in the brain." (said at 0:04:43)
Human and animal studies confirm that only minimal dietary fructose crosses the blood-brain barrier under physiological conditions, but the brain produces fructose endogenously from glucose via the polyol pathway (aldose reductase and sorbitol dehydrogenase). In humans undergoing hyperglycemic clamp experiments, intracerebral fructose increased significantly in response to elevated cerebral glucose. Mechanistic studies and reviews also demonstrate that high-glycemic loads and hyperosmolar stimuli (such as high salt) activate aldose reductase, driving endogenous fructose production in tissues including the hypothalamus.
- supports: The human brain produces fructose from glucose. (JCI insight 2017) · cited 95x in the literature
"To determine whether fructose can be endogenously generated from glucose via the polyol pathway (glucose → sorbitol → fructose) in human brain, 8 healthy subjects... underwent 1 H magnetic resonance spectroscopy scanning to measure intracerebral glucose and fructose levels during a 4-hour hyperglycemic clamp (plasma glucose, 220 mg/dl)... Intracerebral fructose levels also rose over time, differing from baseline at 30 to 230 minutes. The changes in intracerebral fructose were related to changes in intracerebral glucose but not to plasma fructose levels. Our findings suggest that the polyol pathway contributes to endogenous CNS production of fructose" (abstract, results and conclusions)
pubmedfull study (doi) - supports: Endogenous fructose production: what do we know and how relevant is it? (Current opinion in clinical nutrition and metabolic care 2019) · cited 39x in the literature
"Over the recent years, the activation of the polyol pathway and endogenous fructose production has been observed in multiple tissues including the liver, renal cortex, and hypothalamic areas of the brain. The activation occurs during the development and progression of metabolic syndrome and kidney disease and results from different stimuli including osmotic effects, diabetes, and ischemia." (abstract, results, passage verified)
pubmedfull study (doi)
A June 2016 study in Scientific Reports examining 18 postmortem brains (9 with and 9 without Alzheimer's) found that fructose and sorbitol were increased four- to six-fold in Alzheimer's brains compared to controls.
"You had one literature citation in the book that was from, I think, June of 2016, Scientific Reports, where researchers demonstrated—I think there's a handful, 18 postmortem, nine with and nine without Alzheimer's—that the level of fructose and its immediate precursor from glucose, sorbitol, are increased four- to six-fold in the Alzheimer's brain in comparison to the non-Alzheimer's-afflicted brain." (said at 0:07:17)
The host accurately cites a June 2016 study published in Scientific Reports (Xu et al., PMID 27276998). The researchers analyzed postmortem brain tissue from 9 Alzheimer's disease patients and 9 age-matched controls (18 total) across seven brain regions and found significant elevations in glucose, sorbitol, and fructose throughout the Alzheimer's brains. Because this is a small postmortem observational study (n=18), the GRADE certainty for the underlying physiological phenomenon is low.
Fluorodeoxyglucose (FDG) brain imaging studies show that cerebral glucose utilization is compromised in signature Alzheimer's regions long before cognitive symptoms appear.
"I often quote an interesting study that looks at being predictive by doing these FDG, these fluorodeoxyglucose, studies that show brain glucose utilization being compromised in these Alzheimer's signature regions long before people are having these cognitive manifestations." (said at 0:08:25)
Extensive neuroimaging literature and large prospective cohort studies (e.g., ADNI and the Harvard Aging Brain Study) establish that fluorodeoxyglucose (FDG) PET detects reduced cerebral glucose metabolism in signature Alzheimer's disease regions (such as the posterior cingulate, temporoparietal cortex, and entorhinal cortex) in preclinical, cognitively unimpaired individuals, and that baseline hypometabolism is predictive of subsequent cognitive decline and conversion to dementia.
- supports: Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Dis… (Neurology 2021) · cited 32x in the literature
"In preclinical Alzheimer disease, entorhinal hypometabolism is a strong and independent predictor of subsequent cognitive decline, making FDG a potentially useful biomarker to increase power in clinical trials." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Cerebral glucose metabolism in Alzheimer's disease. (Cortex; a journal devoted to the study of the nervous system and behavior 2024) · cited 28x in the literature
"AD FDG-PET pattern was reported in preclinical AD stages and related to cognition or to conversion to mild cognitive impairment (MCI)." (abstract, passage verified)
pubmedfull study (doi) - supports: Baseline FDG-PET Brain hypometabolism as a predictive biomarker of cognitive decline and A… (The journal of nutrition, health & aging 2026) · cited 2x in the literature
"Brain glucose hypometabolism precedes cognitive decline in Alzheimer's disease, however its role in determining long-term cognitive trajectories remains under studied in current literature in a clear manner... Among cognitively normal participants, low glucose metabolism increased Alzheimer's disease conversion risk four-fold (incidence rate ratio = 3.79, 95%CI: 2.94-4.88)." (abstract, background and results, passage verified)
pubmedfull study (doi)
The enzyme AMP deaminase is elevated in the brains of patients with Alzheimer's disease.
"there's an enzyme that's turned on when fructose is metabolized, and we think it's the key enzyme that drives this survival switch, this energy shift, and it's called AMP deaminase. But that enzyme is elevated—AMP deaminase is high in the brains of patients with Alzheimer's." (said at 0:12:00)
Postmortem human brain tissue studies confirm that AMP deaminase enzymatic activity, protein, and mRNA expression are elevated in patients with Alzheimer's disease compared to age-matched controls (showing 1.6- to 2.4-fold increases across multiple examined brain regions). Because this evidence comes from small observational postmortem studies, certainty is rated as low.
A study published in JAMA evaluating inosine to raise uric acid in Parkinson's disease patients showed that inosine was ineffective at improving scores on the UPDRS rating scale.
"Now we see, I guess about six months ago in JAMA, that a study came out doing that in fact—giving inosine, raising uric acid levels, and then evaluating Parkinson's patients on what's called the Unified Parkinson's Disease Rating Scale, UPDRS, and actually found it was ineffective." (said at 0:18:55)
The speaker accurately describes the SURE-PD3 phase 3 randomized clinical trial published in JAMA (2021). The trial randomized 298 patients with early Parkinson's disease to receive either inosine (to elevate serum urate concentrations) or placebo. The primary outcome was the rate of change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score. Although inosine successfully raised serum urate levels, the study was halted early for futility because there was no significant difference in MDS-UPDRS progression rates between the inosine and placebo groups.
- supports: Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Ran… (JAMA 2021) · cited 162x in the literature
"Clinical progression rates were not significantly different between participants randomized to inosine (MDS-UPDRS score, 11.1 [95% CI, 9.7-12.6] points per year) and placebo (MDS-UPDRS score, 9.9 [95% CI, 8.4-11.3] points per year; difference, 1.26 [95% CI, -0.59 to 3.11] points per year; P = .18)... Among patients recently diagnosed as having PD, treatment with inosine, compared with placebo, did not result in a significant difference in the rate of clinical disease progression. The findings do not support the use of inosine as a treatment for early PD." (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
Gout patients can develop uric acid crystal deposits in their blood vessels and kidneys in addition to their joints.
"Patients with gout have these crystals in their joints, but we're now discovering that they can get crystals in their blood vessels and in their kidneys and other sites." (said at 0:20:40)
Modern advanced imaging techniques—specifically dual-energy computed tomography (DECT)—as well as histopathological and autopsy studies have confirmed that patients with gout can develop monosodium urate (MSU) crystal deposits in extra-articular tissues beyond the joints. This includes the vasculature (e.g., coronary arteries, aorta, and peripheral vessels), the kidneys (interstitial MSU deposition and uric acid nephrolithiasis), and other anatomical sites (e.g., the spine, eyes, and skin).
- supports: Systemic Urate Deposition: An Unrecognized Complication of Gout? (Journal of clinical medicine 2020) · cited 66x in the literature
"Recent diagnostic testing, such as dual energy computed tomography (DECT), has led to the recognition that urate deposits are not uncommon in other tissues including the vasculature. To understand the potential risks for untreated gout, we reviewed the literature on extra-articular urate deposition documented by autopsy, histopathology, surgery, and radiology, including the heart, blood vessels, kidney, spine, eye, skin, and gastrointestinal system." (abstract, passage verified)
pubmedfull study (doi) - supports: What Has Dual Energy CT Taught Us About Gout? (Current rheumatology reports 2021) · cited 18x in the literature
"DECT also has the ability to detect vascular MSU deposition. This correlates with high coronary calcium scores and elevated Framingham cardiovascular risk. DECT continues to aid our understanding of articular and extra-articular MSU deposition, including the role of vascular MSU deposition on cardiovascular health." (abstract, passage verified)
pubmedfull study (doi)
Extracellular uric acid reacts with certain radicals like peroxynitrite to remove them, but transiently generates peroxynitrite-like radicals in the process.
"uric acid does block some forms of oxidative stress, but it also can generate oxidative stress even extracellularly because when it reacts with certain radicals, it produces new radicals. And this is a problem of oxidants and antioxidants, and some of them can become a radical of themselves when they bind an oxidant. So they remove peroxynitrite, but they produce a peroxynitrite-like radical at least transiently." (said at 0:21:12)
The claim accurately reflects established biochemical findings regarding uric acid's dual antioxidant/pro-oxidant role. In vitro chemical studies demonstrate that uric acid scavenges peroxynitrite, but the reaction generates urate-derived free radicals (specifically identified as aminocarbonyl radicals and urate radicals), which can transiently propagate lipid peroxidation and other oxidative processes extracellularly.
- supports: Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and ampl… (Archives of biochemistry and biophysics 1999) · cited 276x in the literature
"Our results demonstrated that urate reacts with peroxynitrite with an apparent second order rate constant of 4.8 x 10(2) M(-1). s(-1) in a complex process, which is accompanied by oxygen consumption and formation of allantoin, alloxan, and urate-derived radicals. The main radical was identified as the aminocarbonyl radical by the electrospray mass spectra of its 5, 5-dimethyl-l-pyrroline N-oxide adduct... Production of the aminocarbonyl radical, however, may propagate oxidative reactions. We demonstrated that this radical is likely to be the species responsible for the effects of urate in amplifying peroxynitrite-mediated oxidation of liposomes and LDL" (abstract, results and conclusions, passage verified)
pubmedfull study (doi)
Clinical studies in Spain have investigated intravenous uric acid infusion acutely in stroke patients and suggested potential acute benefits.
"if you have a stroke, there's a group in—I believe the guy is in Spain, but he has done some studies where they've infused uric acid acutely in stroke, and they actually think that it might provide a little bit of benefit acutely." (said at 0:22:00)
The speaker's claim is supported by the URICO-ICTUS trial and its subsequent analyses, led by Dr. Angel Chamorro's group in Spain. In this randomized, double-blind, placebo-controlled phase 2b/3 trial, patients with acute ischemic stroke received an intravenous infusion of 1000 mg of uric acid (or placebo) during alteplase administration (PMID: 24703208). Although the primary outcome (excellent functional outcome at 90 days) did not reach statistical significance in the overall cohort (39% vs 33%, p=0.099), subsequent analyses suggested potential acute benefits, such as a reduction in early ischemic worsening (PMID: 27758945) and improved outcomes in patients who also underwent mechanical thrombectomy (PMID: 28345429).
- supports: Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised… (The Lancet. Neurology 2014) · cited 280x in the literature
"URICO-ICTUS was a randomised, double-blind, placebo-controlled, phase 2b/3 trial that recruited patients with acute ischaemic stroke admitted to ten Spanish stroke centres. Patients were included if they were aged 18 years or older, had received alteplase within 4·5 h of symptom onset... Patients were randomly allocated (1:1) to receive uric acid 1000 mg or placebo (both infused intravenously in 90 min during the infusion of alteplase)..." (abstract, methods, passage verified)
pubmedfull study (doi) - supports: Uric Acid Therapy Prevents Early Ischemic Stroke Progression: A Tertiary Analysis of the U… (Stroke 2016) · cited 81x in the literature
"UA therapy may prevent EIW after acute stroke in thrombolysed patients. Optimal access of UA to its molecular targets through appropriate collaterals may modify the magnitude of the neuroprotective effect." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue… (International journal of stroke : official journal of the International Stroke Society 2017) · cited 76x in the literature
"Uric acid therapy was safe and improved stroke outcomes in stroke patients receiving intravenous thrombolysis followed by thrombectomy." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Mitochondrial oxidative stress induced by uric acid inhibits aconitase in the Krebs cycle, stimulating citrate accumulation, fat production, and insulin resistance while blocking beta-oxidation of fatty acids.
"when you create oxidative stress inside the cell, and especially in the mitochondria, the place where ATP is made, what the oxidative stress does is it works on the Krebs cycle to inhibit it. And it inhibits a specific enzyme called aconitase, and this enzyme is involved in the ATP production that's produced through the Krebs cycle. When it does that, it shifts—it causes a stimulation of citrate, which actually activates a pathway that leads to fat production. And so what happens is that oxidative stress is actually important in the stimulation of fat synthesis. So it stimulates the cell to produce fat, it also is involved in the insulin resistance that develops, and it also blocks the burning of fatty acids, what we call the beta fatty acid cycle." (said at 0:23:43)
The speaker's description matches the mechanism reported in published laboratory studies (mostly in cell cultures and animal models). Specifically, Lanaspa et al. (2012, PMID: 23035112) demonstrated that intracellular uric acid generates mitochondrial oxidative stress, which inhibits mitochondrial aconitase in the Krebs cycle. This causes accumulation and exportation of citrate to the cytosol, which activates lipogenic enzymes (such as ATP citrate lyase) leading to de novo fatty acid synthesis and insulin resistance/steatosis. Furthermore, studies on endothelial cells (Sanchez-Lozada et al., 2012, PMID: 23235493) confirmed uric acid-induced aconitase-2 activity reduction alongside decreased expression of enoyl-CoA hydratase-1 (an enzyme involved in beta-oxidation of fatty acids). Because the evidence for this specific biochemical sequence comes from preclinical cell culture and animal models, the grade of certainty is low.
Initial fructose metabolism consumes intracellular ATP, causing intracellular phosphate and ATP levels to fall while suppressing AMP-activated protein kinase (AMPK) activation.
"initially when the fructose is first being metabolized, it burns a lot of ATP. So the ATP levels start to fall, and then when that intracellular phosphate level falls, then it stimulates the sweeping away of the AMP, which is normally regenerated to ATP. So it consumes the ATP, and then it prevents it from being regenerated because the AMP is swept away, and it also blocks an enzyme that helps produce the ATP called AMP-activated protein kinase." (said at 0:27:45)
The speaker accurately outlines the biochemical mechanism of early fructose metabolism. Rapid phosphorylation of fructose by fructokinase (ketohexokinase) consumes ATP and depletes intracellular phosphate and ATP pools. The decline in intracellular phosphate relieves allosteric inhibition of AMP deaminase, driving generated AMP into the purine degradation pathway (leading to uric acid synthesis) rather than allowing its recycling back into ATP or sustained canonical activation of AMP-activated protein kinase (AMPK).
In animal models, blocking fructose metabolism prevents the development of alcohol-induced fatty liver disease despite alcohol exposure.
"in the laboratory animal that would crave alcohol, metabolize alcohol, ultimately develop alcoholic fatty liver disease, that by blocking the metabolism of fructose, though they were exposed to alcohol, they would not get alcohol-related fatty liver disease" (said at 0:29:40)
The host's statement accurately reflects findings from mouse research investigating ketohexokinase (KHK, the central enzyme in fructose metabolism). In mouse models, alcohol intake stimulates endogenous fructose production, and both global and liver-specific KHK knockout mice were protected from alcohol-associated liver disease, demonstrating marked reductions in hepatic steatosis (fatty liver), inflammation, and fibrosis even under pair-matched alcohol exposure conditions. Because the available evidence consists entirely of preclinical animal studies, the GRADE certainty is very low.
Approximately two-thirds of the purines that produce uric acid in the human body are derived endogenously from tissue recycling rather than from dietary sources.
"recognizing then that we talk about purines being an inroad to raising uric acid as well, but really two-thirds of those purines are not dietary, they're endogenous from recycling of tissue." (said at 0:18:33)
The host's statement accurately reflects standard purine biochemistry and urate physiology: the majority (roughly two-thirds or more) of the purines contributing to uric acid production in humans are generated endogenously through cellular breakdown and turnover of nucleic acids, whereas dietary intake accounts for the remaining minority (approximately one-third).
Elevated serum uric acid levels are associated with an increased risk of stroke.
"There are some studies in patients with stroke where it's been shown that if you have a high uric acid, you're at an increased risk for stroke, that's for sure." (said at 0:21:00)
Multiple systematic reviews and meta-analyses of prospective cohort studies confirm that elevated serum uric acid (SUA) levels are significantly associated with an increased risk of stroke, including both ischemic and hemorrhagic stroke.
Sugar, high-fructose corn syrup, and soft drinks are major risk factors for non-alcoholic fatty liver disease (NAFLD).
"But sugar and high-fructose corn syrup and soft drinks are a major risk factor for fatty liver, non-alcoholic fatty liver disease." (said at 0:30:35)
The claim is supported by extensive evidence from both observational meta-analyses and controlled clinical trials. A dose-response meta-analysis of observational studies (PMID: 31234281) demonstrated that sugar-sweetened beverage consumption is associated with a 39% overall increase in the odds of NAFLD in a dose-dependent manner (reaching a 53% increase with ≥7 cups/week). Furthermore, a meta-analysis of 51 controlled feeding trials (PMID: 35889803) showed with high GRADE certainty that adding excess calories from fructose-containing sugar-sweetened beverages directly increases intrahepatocellular lipid (liver fat) accumulation.
Non-alcoholic fatty liver disease and alcoholic liver disease share biochemical abnormalities including low AMP, high oxidative stress, and elevated uric acid.
"And the two have some of the same biochemical problems, like AMP is low in both, oxidative stress is high in both, uric acid is high in both, and so forth." (said at 0:31:55)
Published human, animal, and mechanistic literature confirms that non-alcoholic fatty liver disease (NAFLD/MASLD) and alcohol-associated liver disease (ALD) share key biochemical pathways. Both fructose/nutrient overload in NAFLD and ethanol metabolism in ALD drive nucleotide turnover (via AMP deaminase activation leading to transient depletion of cellular ATP/AMP and rapid purine degradation), elevated uric acid generation, and increased oxidative stress and reactive oxygen species.
- supports: Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Hu… (Hepatology (Baltimore, Md.) 2020) · cited 50x in the literature
"We demonstrated in liver specimens from patients with alcoholic hepatitis, the AR up-regulation and elevated AR metabolites (sorbitol, fructose, and uric acid), which correlated significantly with (1) increased lipid peroxidation byproducts and endoplasmic reticulum (ER) stress, (2) decreased protective ER chaperones, and (3) greater cell death and liver injury." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fructose and the Liver. (International journal of molecular sciences 2021) · cited 155x in the literature
"Fructose overconsumption may result in insulin resistance, oxidative stress, inflammation, elevated uric acid levels, increased blood pressure, and increased triglyceride concentrations in both the blood and liver. Non-alcoholic fatty liver disease (NAFLD) is a term widely used to describe excessive fatty infiltration in the liver in the absence of alcohol" (abstract, passage verified)
pubmedfull study (doi)
Alcohol consumption activates an enzyme that converts glucose to fructose, causing endogenous fructose synthesis in the liver.
"when you drink alcohol, the alcohol activates an enzyme to make fructose in the body. It's not the alcohol becoming fructose. The alcohol is alcohol, but the alcohol affects an enzyme that's normally not active and it gets turned on by alcohol, and this enzyme converts glucose to fructose and you start making fructose." (said at 0:33:25)
The speaker accurately describes the activation of the polyol pathway by alcohol. Research in human liver specimens and animal models shows that ethanol consumption upregulates aldose reductase (AR), the rate-limiting enzyme of the polyol pathway that converts glucose to sorbitol (which is subsequently converted to fructose). This pathway leads to endogenous fructose generation in the liver and contributes to alcohol-induced metabolic dysfunction and liver injury.
- supports: Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Hu… (Hepatology (Baltimore, Md.) 2020) · cited 50x in the literature
"We demonstrated in liver specimens from patients with alcoholic hepatitis, the AR up-regulation and elevated AR metabolites (sorbitol, fructose, and uric acid), which correlated significantly with (1) increased lipid peroxidation byproducts and endoplasmic reticulum (ER) stress, (2) decreased protective ER chaperones, and (3) greater cell death and liver injury." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Identification of a common ketohexokinase-dependent link driving alcohol intake and alcoho… (Nature metabolism 2025) · cited 4x in the literature
"Ethanol consumption increased portal vein osmolality and activated the polyol pathway in the liver and intestine, leading to fructose production metabolized by KHK-A/C." (abstract, results, passage verified)
pubmedfull study (doi)
A human study showed that aldose reductase is activated and fructose is present in the liver of individuals drinking alcohol.
"And so this group from Kentucky actually did a beautiful study in humans and showed that this enzyme is turned on in the liver of people drinking alcohol and that there's fructose in the liver of people drinking alcohol." (said at 0:34:26)
A 2020 study by researchers investigating alcohol-associated liver disease examined human liver specimens from patients with alcoholic hepatitis (alongside experimental animal models) and demonstrated significant upregulation of aldose reductase (AR) as well as elevated levels of its downstream metabolites, including sorbitol and fructose, in the liver.
In animal models, blocking fructose metabolism or blocking aldose reductase prevents alcohol-induced fatty liver disease.
"when we blocked fructose metabolism, we could block the fatty liver that was induced by alcohol. ... There was a group in China that blocked the enzyme that converts glucose to fructose, and they could block alcoholic liver disease that way in animals too." (said at 0:34:56)
The speaker's statement is supported by animal studies. In mouse models of alcohol-associated liver disease (ALD), genetic knockout of ketohexokinase (KHK-A/C, which blocks fructose metabolism) protects mice against alcohol-induced hepatic steatosis, inflammation, and fibrosis. Similarly, genetic deletion or pharmacological inhibition of aldose reductase (the rate-limiting enzyme of the polyol pathway converting glucose to sorbitol/fructose) prevents alcohol-induced hepatic steatosis and liver injury in rodents. Because the evidence for this specific claim is derived entirely from animal and cell culture models, certainty is rated as very low.
- supports: Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and … (Molecular medicine reports 2017) · cited 21x in the literature
"In addition to the elevation in AR, hepatic steatosis was observed in ethanol diet-fed mice, and this ethanol-induced steatosis was significantly attenuated by inhibiting AR activity with a specific inhibitor, zopolrestat." (abstract, results)
pubmedfull study (doi) - supports: Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Hu… (Hepatology (Baltimore, Md.) 2020) · cited 50x in the literature
"Furthermore, we established a causal role for AR in ALD by showing that the genetic deficiency of AR (knockout mice) prevented alcohol-induced increase in harmful AR metabolites, toxic aldehydes, steatosis, ER stress, apoptosis, and liver injury. Finally, we demonstrated the therapeutic potential of pharmacological AR inhibition against alcohol-induced hepatic injury in experimental ALD." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Identification of a common ketohexokinase-dependent link driving alcohol intake and alcoho… (Nature metabolism 2025) · cited 4x in the literature
"Under ethanol pair-matched conditions, global and liver-specific KHK-A/C knockout mice were protected from ALD, with marked reductions in hepatic steatosis, inflammation and fibrosis." (abstract, results, passage verified)
pubmedfull study (doi)
The polyol pathway via aldose reductase is the only enzymatic pathway by which the body synthesizes endogenous fructose.
"and there's only one way the body makes fructose, only one, and it's through this enzyme called aldose reductase, or what I call the polyol pathway." (said at 0:38:04)
The speaker's statement is biochemically accurate. In mammalian biochemistry, the polyol pathway (in which aldose reductase converts glucose to sorbitol, followed by sorbitol dehydrogenase converting sorbitol to fructose) is the only known enzymatic pathway for the endogenous synthesis of fructose from glucose.
Reduced blood flow during a heart attack stimulates local fructose synthesis in the heart via aldose reductase.
"So it gets turned on, for example, like if you have a heart attack, when the blood flow is low to the heart, that will stimulate local production of fructose in the heart." (said at 0:38:35)
The speaker accurately describes the activation of the polyol pathway during myocardial ischemia. Under conditions of reduced blood flow (such as during a myocardial infarction or cardiac ischemia), flux through aldose reductase is stimulated, initiating the two-step polyol pathway where glucose is reduced to sorbitol by aldose reductase and subsequently oxidized to fructose by sorbitol dehydrogenase. Evidence for this local cardiac pathway activation and its contribution to ischemic injury comes primarily from animal models and preclinical tissue studies.
Elevated uric acid levels directly stimulate and activate aldose reductase, driving further endogenous fructose production.
"When uric acid goes up, it activates aldose reductase. So uric acid is one of the—in fact, we have thought that although uric acid causes this oxidative stress and all these things that are bad, we have considered the possibility that this feedback loop to stimulate aldose reductase may be one of the stronger mechanisms by which uric acid is causing its problems." (said at 0:39:37)
Preclinical in vitro and animal studies demonstrate that uric acid upregulates aldose reductase expression (via oxidative stress and NFAT5 activation), leading to increased endogenous fructose synthesis and establishing a positive feedback loop. Evidence to date is limited to cell culture and rodent models, so certainty is very low.
Obstructive sleep apnea is strongly associated with gout and obesity.
"Obstructive sleep apnea is super associated with gout, it's really associated with obesity." (said at 0:43:24)
Obstructive sleep apnea (OSA) is robustly associated with both gout (and elevated serum uric acid) and obesity. Systematic reviews and meta-analyses show that patients with OSA have a significantly increased risk of developing gout (RR ~1.29) and higher serum uric acid levels, which improve with CPAP therapy. Furthermore, obesity is one of the strongest established risk factors for OSA, with individuals with obesity having nearly a 5-fold higher odds of having OSA compared to normal-weight individuals (OR 4.84).
Obesity is associated with an increased risk for breast cancer, pancreatic cancer, and colon cancer.
"people with obesity have an increased risk for breast cancer and pancreatic cancer and colon cancer." (said at 0:44:48)
A landmark umbrella review of systematic reviews and meta-analyses (Kyrgiou et al., 2017, BMJ) evaluated the evidence across 36 cancer sites and found that adiposity/obesity is supported by strong epidemiological evidence as a risk factor for colon cancer, pancreatic cancer, and postmenopausal breast cancer.
In mice lacking functional uricase or with uricase inhibited, cancers metastasize much faster in the presence of high uric acid.
"So we took mice and we knocked out their uricase or we inhibited it in both ways, and when we give them a cancer, it metastasizes much, much faster in the setting of a high uric acid and an absence of uricase." (said at 0:47:20)
The speaker's description matches published experimental findings in rodent models. A 2021 study evaluated breast cancer cell progression in mice with uricase inactivated either genetically (uricase knockout) or pharmacologically (inhibition with oxonic acid), as well as in uricase-transgenic mice. The authors found that loss or inhibition of uricase (which leads to elevated uric acid levels) was associated with a substantial increase in tumor growth and metastases, whereas transgenic uricase expression reduced tumor growth. Because the supporting evidence comes strictly from animal models, the GRADE certainty is very low.
SARS-CoV-2 replicates more efficiently in a glycolytic environment.
"I reviewed a study last night that made it very clear that SARS-CoV-2 virus replicates much more efficiently in a glycolytic environment." (said at 0:48:20)
In vitro and cellular metabolic studies demonstrate that SARS-CoV-2 infection induces metabolic reprogramming toward aerobic glycolysis, and elevated glucose or a glycolytic cellular environment directly facilitates and accelerates viral replication. Studies in human monocytes and lung epithelial cells show that inhibiting glycolysis (e.g., via 2-deoxy-D-glucose) markedly reduces viral replication, while increasing glycolytic flux enhances viral yield. Because the evidence is based on in vitro and ex vivo cellular experiments, the GRADE certainty is rated as low.
Hospitalized COVID-19 patients with elevated baseline uric acid have a twofold to threefold increased risk of ICU admission, mechanical ventilation, or death.
"And when we look at that juxtaposed upon the studies that are demonstrating that risk for bad outcome, be it ventilator, ICU, or death, is certainly at least twofold increased, if not threefold, or the composite score having all three is threefold increased in people who enter the hospital with a high uric acid level" (said at 0:48:43)
A retrospective cohort study of 1,854 hospitalized COVID-19 patients (PMID 34025575) evaluated admission serum uric acid levels and adverse outcomes. Patients with elevated baseline serum uric acid (≥423 µmol/L) had a 2.60-fold increased risk of the composite outcome (ICU admission, mechanical ventilation, or death; OR 2.60, 95% CI 1.07-6.29) and a 3.01-fold increased risk of mechanical ventilation (OR 3.01, 95% CI 1.06-8.51). The study also noted a U-shaped relationship, where low serum uric acid levels were also associated with approximately twofold increased risk. Certainty is low due to the observational, retrospective design.
In animal experiments, high-salt intake leads to obesity and diabetes through endogenous fructose production, and blocking fructose metabolism prevents this high-salt-induced obesity.
"We put them on salt, you know, there's not much going on for the first two or three months, and then suddenly a little bit later on they start getting fat, and then they get really fat, and they become enormously fat and diabetic. And we can show that it was due to this production of fructose, because if we block their ability to metabolize fructose, even though they're not getting any in their diet, we can block obesity." (said at 0:57:25)
The speaker's claim accurately describes findings published in PNAS (Lanaspa et al., 2018). In mice, high-salt intake triggered endogenous fructose production and metabolism via the aldose reductase–fructokinase pathway, driving hyperphagia, leptin resistance, obesity, and insulin resistance/diabetes. Blocking fructose metabolism (via fructokinase knockout) protected the animals from high-salt-induced obesity. Because this evidence is derived from preclinical animal models, the GRADE certainty is very low for direct application to humans.
Circulating vasopressin, measured via copeptin, is elevated in people with obesity.
"And we actually know that people who are overweight have high vasopressin levels in their blood, and it's the test that's usually measured is called copeptin, but it's a it's like it's a stable measurement of vasopressin and it's high in people with obesity." (said at 0:59:34)
Large population-based observational cohort studies and clinical reviews confirm that copeptin—a stable surrogate marker reflecting circulating arginine vasopressin (AVP) secretion—is significantly elevated in individuals with overweight and obesity, and correlates positively with BMI, waist circumference, and the risk of developing abdominal obesity.
- supports: Plasma copeptin, a unifying factor behind the metabolic syndrome. (The Journal of clinical endocrinology and metabolism 2011) · cited 182x in the literature
"Copeptin quartile (lowest quartile as reference) was, after adjustment for age, sex, insulin, and diabetes mellitus, associated with hypertension (odds ratios 1.04, 1.07, 1.31; P = 0.004), abdominal obesity (odds ratios 1.21, 1.16, 1.57; P = 0.002), obesity (odds ratios 1.25, 1.15, 1.49; P = 0.01)" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: th… (International journal of obesity (2005) 2013) · cited 192x in the literature
"increasing copeptin quartiles predicted incident abdominal obesity (odds ratios 1.55, 1.30 and 1.59; P for trend=0.04)" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspecti… (Current obesity reports 2019) · cited 36x in the literature
"Copeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes." (abstract, results, passage verified)
pubmedfull study (doi)
Vasopressin acts through the V1b receptor to mediate obesity and the metabolic effects of sugar, and blocking the V1b receptor blocks these effects in animals.
"and it's the vasopressin is blocking or is binding to this V1b receptor, and that is important in how obesity occurs, because when you block that receptor, you can block sugar effects." (said at 1:00:10)
Animal research directly supports the claim that vasopressin promotes sugar (fructose)-induced metabolic syndrome and fat accumulation through the V1b receptor. In murine models, deletion or knocking out of the V1b receptor (V1bR-KO) completely protected mice against fructose-induced metabolic syndrome and obesity, whereas activating this pathway enhanced fructokinase expression. Because the supporting evidence comes strictly from preclinical animal knockout models, the GRADE certainty is very low.
Co-administering fructose or sugar with alcohol accelerates alcohol metabolism and increases voluntary alcohol intake in animal models.
"And it's also known that when you give alcohol and sugar together, that the sugar or fructose makes the alcohol more powerful, it accelerates alcohol metabolism, and the two work together. And like if we give an animal alcohol and we give it sugar, it will increase its alcohol intake, and not only that, it will—they will get much more dramatic liver disease." (said at 0:32:55)
Co-administration of fructose or carbohydrate solutions with ethanol accelerates alcohol metabolism and clearance from the bloodstream (often referred to as the 'fructose effect'), demonstrated in both animal models and clinical human trials.
- supports: Fructose-induced increase in ethanol metabolism and the risk of Syndrome X in man. (Comptes rendus biologies 2009) · cited 9x in the literature
"Results show that the administered dose of fructose significantly (P<0.05) reduced the duration of alcohol intoxication by 30.7%, and accelerated the elimination (metabolism) of alcohol from bloodstream by 44.7% (P<0.05)." (abstract, results)
pubmedfull study (doi) - supports: The fructose-dependent acceleration of ethanol metabolism. (Biochemical pharmacology 2021) · cited 9x in the literature
"Ethanol oxidation by rat hepatocytes was increased by more than 50% with the addition of fructose. The stimulation was accompanied by increased glucose, glycerol, lactate and sorbitol production. A similar effect was observed with sorbose, while tagatose had no effect. The same pattern was observed in the in vivo experiments." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Dietary carbohydrate accelerates ethanol elimination, but does not alter hepatic alcohol d… (Alcoholism, clinical and experimental research 1993) · cited 16x in the literature
"In this study, adult female rats, fed chow diets supplemented with fructose or glucose in their drinking water for 10 days demonstrated significantly greater ethanol elimination rates (4.85 +/- 0.28 and 4.92 +/- 1.56 microM ethanol/min/g liver, respectively) than rats receiving water (3.65 +/- 0.29)." (abstract, results, passage verified)
pubmedfull study (doi)
Elevated uric acid causes hypertension by inhibiting endothelial nitric oxide production.
"the metabolism to uric acid, uric acid's inhibition of nitric oxide leading to hypertension. You mentioned before low-grade inflammation within the kidney" (said at 0:58:34)
Extensive mechanistic and experimental evidence demonstrates that elevated uric acid directly impairs endothelial nitric oxide (NO) bioavailability and endothelial nitric oxide synthase (eNOS) phosphorylation, which leads to endothelial dysfunction, increased vascular resistance, and hypertension.
Dietary consumption of either sugar or salt increases circulating levels of vasopressin in animals.
"and when we were giving sugar to animals as well as salt to animals, we found that vasopressin levels went up in the blood." (said at 0:59:50)
Animal experimental studies demonstrate that oral administration of sugars (fructose, glucose, high-fructose corn syrup) as well as salt increases circulating levels of vasopressin (measured directly or via its surrogate biomarker copeptin) in rodent models. Because the claim specifically describes animal experimental findings, the available pre-clinical literature directly supports the statement.
- supports: Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor. (JCI insight 2021) · cited 55x in the literature
"Orally administered fructose, glucose, or high-fructose corn syrup increased vasopressin (copeptin) concentrations and was mediated by fructokinase, an enzyme specific for fructose metabolism." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Sugar, salt, immunity and the cause of primary hypertension. (Clinical kidney journal 2023) · cited 13x in the literature
"Leptin levels rise, triggering activation of the sympathetic central nervous system, while vasopressin levels rise, causing vasoconstriction in its own right and stimulating aldosterone production via the vasopressin 1b receptor. Low-grade renal injury and autoimmune-mediated inflammation occur. High-salt diets can amplify this process by raising osmolality and triggering more fructose production." (abstract, results, passage verified)
pubmedfull study (doi)
Activation of the polyol pathway by glucose, along with elevated sodium and hypoxia, contributes to acquired mitochondrial dysfunction.
"the glucose through activation of the polyol pathway, elevated sodium, hypoxia, big belly, all that stuff feeding into ultimately this acquired mitochondropathy as being a, you know, the bioenergetic explanation" (said at 1:02:31)
Activation of the polyol pathway (aldose reductase pathway) by excess glucose shunts glucose into sorbitol and fructose, depleting NADPH and NAD+, generating reactive oxygen species, and directly impairing mitochondrial bioenergetics and dynamics. Reviews of diabetic and metabolic pathophysiology confirm that polyol pathway activation, alongside hypoxia and related metabolic stressors, drives acquired mitochondrial dysfunction and bioenergetic failure.
- supports: Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic Retinopathy. (Journal of clinical & experimental ophthalmology 2013) · cited 126x in the literature
"Excess glucose metabolic flux through the aldose reductase/polyol pathway, advanced glycation end product (AGE) formation, elevated hexosamine biosynthesis pathway (HBP), diacyl glycerol/PKC activation, and mitochondrial ROS generation are all implicated in DR. In addition, endoplasmic reticulum stress/unfolded protein response (er-UPR) and deregulation of mitochondrial quality control by autophagy/mitophagy are observed causing cellular bioenergetic deficiency and injury." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Involvement of cellular and enzymatic aspects in the complexity of diabetic neuropathy. (Tissue barriers 2026) · cited 2x in the literature
"Chronic hyperglycemia activates several enzymatic pathways that exacerbate oxidative stress, mitochondrial dysfunction, and vascular impairment. Among the pivotal enzymes involved is aldose reductase, which drives the polyol pathway and sorbitol accumulation" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Signaling complexity in diabetic neuropathy: a multitargeted perspective on pathogenesis a… (Journal of receptor and signal transduction research 2026) · cited 3x in the literature
"Among the metabolic contributors, polyol pathway, AGE, PKC pathway, and hexosamine biosynthetic pathway are key players. These are closely intertwined with inflammatory mediators and pathways... Mitochondrial dysfunction and oxidative stress, exacerbated by the impairment of AMPK/SIRT/PGC-1α and Nrf2 signaling, contribute to cellular damage and bioenergetic failure." (abstract, results)
pubmedfull study (doi)
Uric acid is a downstream metabolite of fructose.
"fructose and its downstream metabolite, uric acid, that tends to amplify all this now-negative aspects of this metabolism, which were once actually survival mechanisms." (said at 1:05:04)
The biochemical pathway linking fructose catabolism to uric acid generation is well established in both animal and human studies. In the liver, fructose is rapidly phosphorylated by ketohexokinase (fructokinase C) without negative feedback, which depletes intracellular ATP and increases AMP. AMP is then converted by AMP deaminase and downstream purine degradation pathways into uric acid.
- supports: Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. (Journal of hepatology 2018) · cited 939x in the literature
"Recent evidence suggests that the predisposition to fatty liver is linked to the metabolism of fructose by fructokinase C, which results in ATP consumption, nucleotide turnover and uric acid generation that mediate fat accumulation." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fructose Metabolism and Disease Mechanisms: From Nutritional Excess to Obesity and Multior… (Frontiers in bioscience (Elite edition) 2026) · cited 1x in the literature
"This review synthesizes current evidence on the biochemical and molecular pathways underlying fructose induced disease mechanisms, discussing how fructose metabolism activates the "survival switch", promotes fat storage, and generates uric acid, mitochondrial dysfunction, and oxidative stress, thereby disrupting energy homeostasis." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.